This site is intended for Healthcare professionals only.

USFDA issues EIR for Granules Indias Gagillapur plant


USFDA issues EIR for Granules Indias Gagillapur plant

New Delhi: Drug firm Granules India on Wednesday said the US health regulator has issued establishment inspection report for its Gagillapur plant in Hyderabad without any observations.

The United States Food and Drug Administration (USFDA) has issued establishment inspection report (EIR) for the company’s Gagillapur facility in Hyderabad, Granules India said in a regulatory filing.

“The facility was inspected by the USFDA in October 2016 and there were no observations during the inspection”, it added.

Finished dosages and pharmaceutical formulation intermediates are manufactured at the plant, it said.



Source: PTI
0 comment(s) on USFDA issues EIR for Granules Indias Gagillapur plant

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted